Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen Receives $187K Grant from Michael J. Fox Foundation

NEW YORK (GenomeWeb News) – Lucigen today announced it has received a $187,000 grant from the Michael J. Fox Foundation to study a protein that has been implicated in Parkinson's disease.

Research will be directed at LRRK2, a protein found throughout the brain. Lucigen said that researchers are particularly interested in how LRRK2 responds to different drug compounds. Small chemical compounds that may inhibit this enzyme may be useful in shedding light on the mechanisms of Parkinson's and ultimately lead to effective treatments for the disease.

The goal of the grant is to develop an inexpensive, high-throughput method for screening compounds that may inhibit LRRK2.

"This grant enables Lucigen to utilize our core strengths in protein engineering, along with a proprietary fluorescent protein previously isolated by Lucigen, in order to advance medical research into a devastating disease," David Mead, CEO of the company, said in a statement.

The Middleton, Wis.-based firm said that several new research positions have been added as part of the grant.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.